SH3RF2: A Novel Tumor Suppressor Gene and Its Potential Role in Ovarian Cancer and Cisplatin Resistance

SH3RF2 (SH3 Domain Containing Ring Finger 2) is a member of the E3 ubiquitin ligase family, and the SH3RF2 gene plays an important role in various physiological processes. For example, it is involved in cell proliferation and differentiation, and regulates the progression of the cell cycle. In addition, the SH3RF2 gene is also involved in cell migration and invasion, and has a significant impact on tumor development and metastasis. SH3RF2 is a newly discovered tumor suppressor gene, which plays a crucial regulatory role in the occurrence and development of tumors. Mutations and abnormal expression of the SH3RF2 gene are associated with the occurrence and development of various diseases. For example, in common tumors such as breast cancer, lung cancer, and gastric cancer, the expression level of SH3RF2 is significantly lower than that in normal tissues. In ovarian cancer, the expression level of SH3RF2 is significantly correlated with the survival rate of ovarian cancer patients. Patients with low expression levels have a lower survival rate, and mutations or deletions of SH3RF2 are closely related to the occurrence and development of ovarian cancer. A study found that the mutation rate of the SH3RF2 gene is higher in ovarian cancer and is associated with tumor grade and prognosis, suggesting that SH3RF2 mutations may be a driving factor in ovarian cancer. However, there is currently no research on the association between SH3RF2 and cisplatin resistance in ovarian cancer. Therefore, this study aims to explore whether this gene is associated with cisplatin resistance and investigate its molecular mechanisms, providing a theoretical basis for exploring SH3RF2 as a potential therapeutic target.